Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months
- Resource Type
- Authors
- Dennis Riff; Eric Sheldon; Ping Li; George Risi; Joanne M. Langley; Louis Fries; David W. Vaughn; Louise Frenette
- Source
- Vaccine. 31(2)
- Subject
- Male
Adult
Adolescent
Influenza vaccine
medicine.medical_treatment
Population
Immunization, Secondary
Booster dose
medicine.disease_cause
Antibodies, Viral
Adjuvants, Immunologic
Influenza, Human
Influenza A virus
medicine
Humans
AS03
education
Antigens, Viral
Immunization Schedule
education.field_of_study
Reactogenicity
General Veterinary
General Immunology and Microbiology
Influenza A Virus, H5N1 Subtype
business.industry
Immunogenicity
Vaccination
Public Health, Environmental and Occupational Health
Middle Aged
Antibodies, Neutralizing
Infectious Diseases
Influenza Vaccines
Immunology
Molecular Medicine
Female
business
Adjuvant
- Language
- ISSN
- 1873-2518
One influenza pandemic preparedness strategy involves priming a population with a pre-pandemic subtype-specific vaccine and boosting the immunological response at the time of the pandemic with a strain-matched vaccine. In the current study, adults (n=469) randomised 15 months previously to receive an A/Indonesia/5/2005 (H5N1) influenza vaccine (3.75 μg haemagglutinin antigen [HA]) administered alone or in combination with an oil-in-water emulsion based Adjuvant System containing 11.86 mg (AS03(A)) or 5.93 mg (AS03(B)) tocopherol per dose, received one booster dose of A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) with or without AS03(A). An anamnestic antibody response that met US regulatory acceptance criteria was observed 15 months after priming. Although superior immunogenicity of AS03-adjuvanted compared to unadjuvanted priming was not demonstrated, higher antibody titres which persisted longer were seen when both priming and boosting regimens were adjuvanted. This may affect duration of response or heterologous immunity. The booster vaccines had a clinically acceptable safety/reactogenicity profile after adjuvanted or unadjuvanted priming. This study has been registered at www.clinicaltrials.gov NCT00771615.